183 related articles for article (PubMed ID: 35249409)
1. Clinical Impact of the Size of Drug-Coated Balloon Therapy on Restenosis Rate in Femoropopliteal Lesions.
Kurata N; Iida O; Takahara M; Asai M; Masuda M; Okamoto S; Ishihara T; Nanto K; Kanda T; Tsujimura T; Matsuda Y; Hata Y; Mano T
J Endovasc Ther; 2023 Apr; 30(2):269-280. PubMed ID: 35249409
[TBL] [Abstract][Full Text] [Related]
2. Impact of Baseline and Postprocedural Intravascular Ultrasound Findings on 1-Year Primary Patency After Drug-Coated Balloon Treatment of Femoropopliteal Lesions.
Horie K; Tanaka A; Taguri M; Inoue N
J Endovasc Ther; 2022 Feb; 29(1):66-75. PubMed ID: 34781756
[TBL] [Abstract][Full Text] [Related]
3. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
Caradu C; Lakhlifi E; Colacchio EC; Midy D; Bérard X; Poirier M; Ducasse E
J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
[TBL] [Abstract][Full Text] [Related]
4. Impact of IVUS-Derived Vessel Size on Midterm Outcomes After Stent Implantation in Femoropopliteal Lesions.
Miki K; Fujii K; Tanaka T; Yanaka K; Yoshihara N; Nishimura M; Sumiyoshi A; Horimatsu T; Imanaka T; Fukunaga M; Akahori H; Masuyama T; Ishihara M
J Endovasc Ther; 2020 Feb; 27(1):77-85. PubMed ID: 31948376
[No Abstract] [Full Text] [Related]
5. Angiographic patterns of restenosis after drug-coated balloon angioplasty for femoropopliteal lesions and 1-year prognosis after repeat endovascular therapy.
Higashino N; Iida O; Ishihara T; Hata Y; Toyoshima T; Tsukizawa T; Nishian K; Fujihara M; Kawasaki D; Mano T
Catheter Cardiovasc Interv; 2023 Nov; 102(6):1114-1121. PubMed ID: 37855184
[TBL] [Abstract][Full Text] [Related]
6. Impact of Postoperative Lumen Gain on the Reduction of Restenosis Risk after Endovascular Treatment using Drug-coated Balloon for Femoropopliteal Lesions Assessed by Intravascular Ultrasound.
Horie K; Takahara M; Nakama T; Tanaka A; Tobita K; Hayakawa N; Mori S; Iwata Y; Suzuki K
J Atheroscler Thromb; 2023 Sep; 30(9):1142-1151. PubMed ID: 36436877
[TBL] [Abstract][Full Text] [Related]
7. Vessel Patency and Associated Factors of Drug-Coated Balloon for Femoropopliteal Lesion.
Soga Y; Takahara M; Iida O; Tomoi Y; Kawasaki D; Tanaka A; Yamauchi Y; Tobita K; Kozuki A; Fujihara M; Ando K;
J Am Heart Assoc; 2023 Jan; 12(1):e025677. PubMed ID: 36583431
[TBL] [Abstract][Full Text] [Related]
8. Drug-Coated Balloons for Complex Femoropopliteal Lesions: 2-Year Results of a Real-World Registry.
Schmidt A; Piorkowski M; Görner H; Steiner S; Bausback Y; Scheinert S; Banning-Eichenseer U; Staab H; Branzan D; Varcoe RL; Scheinert D
JACC Cardiovasc Interv; 2016 Apr; 9(7):715-24. PubMed ID: 27056311
[TBL] [Abstract][Full Text] [Related]
9. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.
Kokkinidis DG; Behan S; Jawaid O; Hossain P; Giannopoulos S; Singh GD; Laird JR; Valle JA; Waldo SW; Armstrong EJ
Catheter Cardiovasc Interv; 2020 Feb; 95(3):439-446. PubMed ID: 31816169
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and predictors of restenosis in patients with femoropopliteal artery disease treated using polymer-coated paclitaxel-eluting stents or drug-coated balloons.
Yoshioka N; Tokuda T; Koyama A; Yamada T; Nishikawa R; Shimamura K; Takagi K; Morita Y; Tanaka A; Ishii H; Morishima I; Murohara T;
Heart Vessels; 2022 Apr; 37(4):555-566. PubMed ID: 34553242
[TBL] [Abstract][Full Text] [Related]
11. Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis.
Giannopoulos S; Kokkinidis DG; Jawaid O; Behan S; Hossain P; Alvandi B; Foley TR; Singh GD; Waldo SW; Armstrong EJ
Cardiovasc Revasc Med; 2020 Jun; 21(6):771-778. PubMed ID: 31761634
[TBL] [Abstract][Full Text] [Related]
12. Intraluminal vs Subintimal Drug-Coated Balloon Angioplasty for the Treatment of Femoropopliteal Chronic Total Occlusions.
Toyoshima T; Takahara M; Iida O; Tomoi Y; Kawasaki D; Tanaka A; Yamauchi Y; Tobita K; Kozuki A; Fujihara M; Higuchi Y; Soga Y;
JACC Cardiovasc Interv; 2024 Mar; 17(5):608-618. PubMed ID: 38479962
[TBL] [Abstract][Full Text] [Related]
13. Multicenter, retrospective registry of isolated atherosclerotic popliteal arteries treated with endovascular revascularization.
Horie K; Takahara M; Nakama T; Tanaka A; Tobita K; Hayakawa N; Mori S; Iwata Y; Suzuki K
Heart Vessels; 2023 Sep; 38(9):1117-1129. PubMed ID: 37217811
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Intravascular Ultrasound on Femoropopliteal Artery Endovascular Interventions: A Randomized Controlled Trial.
Allan RB; Puckridge PJ; Spark JI; Delaney CL
JACC Cardiovasc Interv; 2022 Mar; 15(5):536-546. PubMed ID: 35272779
[TBL] [Abstract][Full Text] [Related]
15. Two-year clinical outcomes and predictors of restenosis following the use of polymer-coated paclitaxel-eluting stents or drug-coated balloons in patients with femoropopliteal artery disease.
Yoshioka N; Tokuda T; Koyama A; Yamada T; Shimamura K; Nishikawa R; Morita Y; Morishima I;
Heart Vessels; 2023 Mar; 38(3):429-437. PubMed ID: 36169709
[TBL] [Abstract][Full Text] [Related]
16. Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.
Krishnan P; Farhan S; Schneider P; Kamran H; Iida O; Brodmann M; Micari A; Sachar R; Urasawa K; Scheinert D; Ando K; Tarricone A; Doros G; Tepe G; Yokoi H; Laird J; Zeller T
J Am Coll Cardiol; 2022 Sep; 80(13):1241-1250. PubMed ID: 36137674
[TBL] [Abstract][Full Text] [Related]
17. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
J Endovasc Ther; 2018 Feb; 25(1):109-117. PubMed ID: 29264999
[TBL] [Abstract][Full Text] [Related]
18. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
Scheinert D; Duda S; Zeller T; Krankenberg H; Ricke J; Bosiers M; Tepe G; Naisbitt S; Rosenfield K
JACC Cardiovasc Interv; 2014 Jan; 7(1):10-9. PubMed ID: 24456716
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
[No Abstract] [Full Text] [Related]
20. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
